Podcasts about immunitybio

  • 22PODCASTS
  • 38EPISODES
  • 1hAVG DURATION
  • ?INFREQUENT EPISODES
  • May 30, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about immunitybio

Latest podcast episodes about immunitybio

AUAUniversity
Highlights from AUA2025: Advances in NMIBC (2025)

AUAUniversity

Play Episode Listen Later May 30, 2025 68:54


Highlights from AUA2025: Advances in NMIBC (2025) CME Available: https://auau.auanet.org/node/43167 At the conclusion of this CME activity, participants will be able to: 1. Recognize recent developments in the management of NMIBC. 2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events. 3. Employ current management approaches for NMIBC. 4. Utilize risk stratification to guide treatment decisions for NMIBC patients. 5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. This educational activity is supported by independent educational grants from: Merck & Co., Inc. ImmunityBio, Inc.

Ask Dr. Drew
Dr. Patrick Soon-Shiong: LA Times Owner on CA Wildfire Disaster, Ending Newsroom Bias Against Conservatives & Why He Supports RFK – Ask Dr. Drew – Ep 454

Ask Dr. Drew

Play Episode Listen Later Feb 14, 2025 85:06


As owner of the historic Los Angeles Times newspaper, Dr. Patrick Soon-Shiong has said its endorsement of Los Angeles Mayor Karen Bass was a mistake, suggested that his newsroom should add AI “bias meters” to ensure objectivity, and vocally supported RFK by saying Kennedy “knows more about the science than most doctors.” His push to diversify the LA Times' political viewpoints led to multiple resignations by editors and columnists, who were uncomfortable with his intention to balance the paper's opinion section with more centrist and conservative writers. Dr. Patrick Soon-Shiong is a physician, surgeon, and biotech entrepreneur who has pioneered treatments for diabetes and cancer. In 2018, he became the owner of the Los Angeles Times. He serves as Executive Chairman of ImmunityBio and holds over 675 worldwide patents. In 1993, he performed UCLA's first whole-organ pancreas transplant and developed Abraxane, an FDA-approved cancer drug. Soon-Shiong is Chairman of NantWorks, recipient of the 2016 Franklin Institute Bower Award, minority owner of the Los Angeles Lakers, and healthcare advisor to Botswana's President. Read the LA Times at https://latimes.com and follow Dr. Soon-Shiong at https://x.com/DrPatSoonShiong 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

AUAUniversity
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists

AUAUniversity

Play Episode Listen Later Dec 25, 2024 74:46


Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.

Let's Talk Quality
Sang Yoon on creating a community first, a company second.

Let's Talk Quality

Play Episode Listen Later Dec 11, 2024 33:32


On this week's episode of Let's Talk Quality: The Podcast

Urology Care Podcast
Non-Muscle Invasive Bladder Cancer Basics with Dr. Kyle Richards

Urology Care Podcast

Play Episode Listen Later Dec 6, 2024 12:52


Our guest is Dr. Kyle Richards, a urologic oncologist and Associate Professor in the Department of Urology at the University of Wisconsin. He talks with us about the basics around non-muscle invasive bladder cancer. Learn about common symptoms, diagnosis and treatment options to start talking with your health care team. For more information, please visit www.UrologyHealth.org and don't forget to subscribe to our free digital magazine, UrologyHealth extra® at www.urologyhealth.org/uhe. Support provided by independent educational grants from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc. **** December 6, 2024

The Daily Business & Finance Show
Tesla Surge, Apple Innovation & Market Shifts (+5 more stories)

The Daily Business & Finance Show

Play Episode Listen Later Oct 26, 2024 6:07


The Daily Business and Finance Show - Saturday, 26 October 2024 We get our business and finance news from Seeking Alpha and you should too! Subscribe to Seeking Alpha Premium for more in-depth market news and help support this podcast. Free for 14-days! Please click here for more info: Subscribe to Seeking Alpha Premium News Today's headlines: Cathie Wood cashes in on Tesla's best day in over a decade by selling shares worth $22M Apple reportedly tests a blood sugar app Nasdaq pulls back after new record, ends higher; S&P snaps six-week win streak ImmunityBio extends gains after trial update UnitedHealth risks billions of dollars in Medicare payments as Feds target home visits Wall Street halts longest weekly win streak of the year ahead of Big Tech earnings Delta sues CrowdStrike over massive July computer outage Google developing AI technology to takeover user's internet browser: report Explanations from OpenAI ChatGPT API with proprietary prompts. This podcast provides information only and should not be construed as financial or business advice. This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating the Latest News and Trends in the Industry

Pharma and BioTech Daily

Play Episode Listen Later Oct 3, 2024 2:26


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bayer has developed a successful audience targeting strategy that drives meaningful engagement, with Crossix audience segments optimizing campaigns and aligning messaging more closely with the patient journey. This precision targeting has proven effective in reaching the most qualified audience and increasing engagement.Philips issued a fix for ventilator problems linked to injuries and deaths, Siemens Healthineers received FDA approval for a 3D mammography system, and Synchron's brain-computer interface technology met safety goals. Additionally, the wearables market is expected to see growth, while the FDA missed a target date for releasing rules on pulse oximeters. Medtech Dive provides insights on medical technology trends and top conferences in 2025.A private equity firm, TPG, is set to acquire a majority stake in e-prescribing giant Surescripts. HCA's Mission Hospital in North Carolina faces challenges after Hurricane Helene, while UHS has been forced to pay significant damages related to child sexual abuse allegations. Efforts to combat burnout among healthcare workers are highlighted, along with sponsored content on safeguarding healthcare against cybercrime.Eli Lilly is investing $4.5 billion in a new manufacturing and research center in Indiana, while Amgen faces a class action lawsuit and Johnson & Johnson invests $2 billion in a North Carolina facility. Bayer, J&J, and Pfizer are collectively laying off nearly 500 employees, with new developments in cFDNA methylation assays and royalty financing for biopharma companies. ImmunityBio is also undergoing layoffs in California.Roche is facing an $8 billion sales gap due to biosimilar competition, prompting investments in new blockbuster drugs. Kailera Therapeutics has secured funding for obesity drugs, and the cell and gene therapy industry is experiencing rapid growth. Pharmavoice covers these topics and more in their daily newsletter.2seventy Bio is close to reaching cash flow breakeven, attributing their survival to transparency and a committed staff. Pfizer's withdrawal of sickle cell therapy Oxbryta has raised questions among investors. Royalty financing has become crucial for biopharma companies as traditional fundraising methods falter. Lilly's drug pricing practices are under scrutiny compared to Novo Nordisk. Various updates on investments, layoffs, and legal actions can be found on Biospace's website.

Business Of Biotech
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné

Business Of Biotech

Play Episode Listen Later Jul 22, 2024 66:39 Transcription Available


We love to hear from our listeners. Send us a message. While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry, and to go to work as a big bio research scientist. Along the way, Dr. Diloné got bit by the biotech business bug. It wasn't easy. A whole bunch of MBA and executive learning programs at Rutgers, MIT, and Harvard, and many years of experience later, he's Chief Technology Officer at Immunity Bio, which he joined in advance of the company winning FDA approval of ANKTIVA, its IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, in April '24. On this episode of the Business of Biotech, we follow Dr. Diloné's path from the bench to the boardroom, and learn how valuable that rare bridge between CMC and the executive offices really is. Register for Bioprocess Online's Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we've broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It's absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

Healthcare Unfiltered
From Apartheid to Abraxane: Dr. Soon-Shiong on Medicine, Entrepreneurship, Business, and Triumph

Healthcare Unfiltered

Play Episode Listen Later Jul 16, 2024 85:43


In this exclusive interview, Chadi welcomes Dr. Patrick Soon-Shiong, a Chinese immigrant who grew up under apartheid in South Africa and rose to become one of the world's most successful physician executives. Now the CEO of ImmunityBio, Dr. Soon-Shiong opens up about his remarkable journey. He shares what inspired him to pursue medicine, his entrepreneurial ventures, his move to the United States, and the story of his first investment. He discusses creating the groundbreaking chemotherapy drug Abraxane, which led to the formation of Abraxis, later acquired by Celgene, now part of BMS. He also expounds on his most recent FDA-approved drug, Anktiva, for bladder cancer. With complete candidness, Dr. Soon-Shiong reflects on his challenging upbringing, the discrimination he faced, and how he overcame these obstacles to achieve great success. He and Chadi explore life lessons, leadership styles, and a range of topics including Kobe Bryant, Gavin Newsom, COVID-19, the first pancreatic transplant, the acquisition of the Los Angeles Times, and his public feud with his brother. This 2024 podcast episode offers an unparalleled glimpse into the life of a highly public and inspiring figure and is one you'll want to listen to more than once and share with everyone you know. Read more about Dr. Soon-Shiong. https://immunitybio.com/our-founder/ Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Biotech Clubhouse
Episode 99

Biotech Clubhouse

Play Episode Listen Later Apr 30, 2024 59:23


On this week's Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Sam Fazeli and Yaron Werber discuss macro updates from the week including President Biden's proposal to increase capital gains and apply a tax on unrealized capital gains and FTC's rule to ban non-competes nationwide. The group also covers the roller coaster ride of Q1 earnings including reports from AstraZeneca, BMS, Novartis and Biogen. In oncology news, the hosts review the underwhelming ASCO titles, Acrivon's positive data for ovarian and endometrial cancers, the FDA approval of ImmunityBio's Anktiva and Sam Blackman from Day One joins the panel to discuss the accelerated approval of OJEMDA. In financings and deals, the hosts cover Xaira Therapeutics $1B raise, Incyte's acquisition of Escient, Metsara's launch in obesity, Cellares/BMS collaboration and a joint venture between Takeda, Astellas and Sumitomo. The hosts also get into a stimulating discussion on liked versus unliked CEOs. *This episode aired on April 26, 2024.

Business Of Biotech
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.

Business Of Biotech

Play Episode Listen Later Apr 15, 2024 56:54 Transcription Available


This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone. You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 29, 2024 85:10


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 29, 2024 84:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 29, 2024 84:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 29, 2024 85:10


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 29, 2024 85:10


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Feb 29, 2024 84:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 17, 2024 61:22


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 17, 2024 61:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 17, 2024 61:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 17, 2024 61:22


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 17, 2024 61:22


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 17, 2024 61:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Biotech Clubhouse
Episode 84

Biotech Clubhouse

Play Episode Listen Later Jan 16, 2024 65:15


In the first Biotech Hangout of 2024, RA Capital's Peter Kolchinsky joins hosts Daphne Zohar, Josh Schimmer, Tim Opler, Paul Matteis and Luba Greenwood to discuss the latest biotech news. They start with the last M&A deals of 2023 including Bristol Myers Squibb's acquisition of Karuna and Rayzebio, and AstraZeneca's acquisition of Gracell. They discuss insights from RA Capital's latest sector analysis and the outlook for the sector in 2024, plus JPM predictions. The hosts also cover news from the first week of 2024 including Longboard Pharmaceuticals and Dyne Therapeutics data, Novartis' expanded collaboration with Voyager, the FDA's hold on Iovance's TIL therapy and their approval of AstraZeneca and Ionis' rare nerve disease treatment. Other topics include Goldman Sachs life science investment fund and ImmunityBio's royalty financing. *This episode aired on January 5, 2024

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 21, 2023 64:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 21, 2023 64:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 21, 2023 64:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 21, 2023 64:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 21, 2023 64:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 21, 2023 64:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 21, 2023 64:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Dec 21, 2023 64:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Biotech Clubhouse
Episode 72

Biotech Clubhouse

Play Episode Listen Later Sep 22, 2023 60:42


Guest Yaron Werber joins hosts Daphne Zohar, Chris Garabedian and Brad Loncar for this week's Biotech Hangout, centered on the theme of ‘management and culture.' They cover the big IPO news of the week from Neumora (~$2.5B valuation) and RayzeBio (~$1B valuation) plus Acelyrin's share value drops after sharing top-line results despite being the largest biotech IPO this year. They also discuss Goldman Sachs dropping its price targets and ratings for “early-stage” biotechs and updates from both Moderna and Roche, who held their R&D days this week. Also, Galapagos' 52-week low and the contrast with Argenx plus the FDA ad comm on Anlylam's cardiomyopathy candidate. Other topics of discussion include 2seventy bio's restructuring, CymbaBay data, ImmunityBio's equity & debt financing & Day One's updated data & FDA filing decision date. *This episode aired on September 15, 2023

The FinTwit Podcast
ImmunityBio $IBRX - Potential Multibaggers - Episode #1

The FinTwit Podcast

Play Episode Listen Later Feb 4, 2022 22:10


Guy goes over a thread on Twitter by Shovel Stocks who tweets about a Biotech Company called ImmunityBio $IBRX. The company has promising immunotherapy technology and also a new T cell Vaccine that could be a difference maker in helping fight this Covid pandemic. This was Episode #1 of a new series we're experimenting with called "Potential Multibaggers". Let us know what you think! Check out the thread that was referenced in this episode: https://twitter.com/shovelstocks/status/1472976657745166339?s=12 Follow Shovel Stocks on Twitter: https://twitter.com/shovelstocks?s=11 Check out the IBRX Stock on Yahoo Finance: https://finance.yahoo.com/quote/IBRX?p=IBRX Follow CEO Pat Soon-Shiong: https://twitter.com/drpatsoonshiong?s=11 Follow ImmunityBio on Twitter: https://twitter.com/immunitybio?s=11 Check out the company website: https://immunitybio.com Check out this Stocktwits Post and follow the company on this platform: https://stocktwits.com/Askalot/message/433300998 Follow Guy on twitter: https://twitter.com/guy_leblanc?s=11 Follow the FinTwit Podcast on Twitter: https://twitter.com/thefintwitpod?s=11 Reminder that nothing in this podcast is financial advice or recommendations to buy, sell or hold any stocks that are mentioned.

Talking with Traders
S04E09: Bruce Main and Willem Van Der Post. Biotech, Helium and Venture Capital

Talking with Traders

Play Episode Listen Later Jan 19, 2022 46:33


Bruce Main is back for a follow-up interview as we ran out of time to pick his brain in our previous interview. This time he covers ImmunityBio and Renergen. He's also brought a colleague with him: Willem Van Der Post from Simple Capital. Willem discusses an exciting new concept: Democratised Venture Capital, available to retail investors via a token.

Amanpour
Amanpour: Svetlana Tikhanovskaya, Chris Krebs, Kurtis Minder and Dr Patrick Soon Shiong

Amanpour

Play Episode Listen Later Jun 9, 2021 55:23


Eexiled Belarusian opposition leader Svetlana Tikhanovskaya joins Bianna Golodryga, standing in for Christiane Amanpour, to assess what democratic countries must do to put pressure on President Lukashenko. As President Biden arrives in the UK for the G7 meeting of leading economies, Chris Krebs, partner at Krebs Stamos Group and a former DHS cybersecurity official, discusses why we're seeing more ransomware attacks with and why dealing with this is a key priority for America. Kurtis Minder, CEO of cyber reconnaissance company GroupSense and ransomware negotiator, explains that many hacking victims have no choice but to pay ransoms, despite government guidance. And our Walter Isaacson speaks to Dr Patrick Soon Shiong, chairman of both the LA Times and ImmunityBio, about the new form of COVID vaccine he's developing which is current in trials in U.S. and his native South Africa. To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Eco d'ici Eco d'ailleurs
Éco d'ici éco d'ailleurs - Pour lutter contre la pandémie, suspendre la propriété intellectuelle des vaccins

Eco d'ici Eco d'ailleurs

Play Episode Listen Later Apr 23, 2021 48:30


Les variants indiens et brésiliens du Covid-19 inquiètent la planète entière par leur contagiosité. Il ne suffira pas aux pays riches de vacciner leur population pour être protégés. Pour vacciner la population de la planète, il faut démultiplier la production. Pour le permettre, de nombreuses voix s’élèvent pour donner un accès libre aux brevets des quelques vaccins mis au point. Il y a deux semaines, nous avions consacré notre rencontre à la question des vaccins, bien publics ou biens privés. Après l’émission, les invités qui étaient tous au téléphone ont continué à parler. Mais ce qui s’est passé, ce jour-là, le démontrait à l’envie, la question était loin d’être épuisée. D'où cette seconde émission où nous allons plus précisément nous interroger sur les brevets des vaccins, sur la propriété intellectuelle de ces vaccins et sur l’impact que la pandémie a eu sur le financement des systèmes de santé. Mais, chacune et chacun des précédents invités ayant un agenda très chargé, la plupart d’entre eux n’ont pas pu répondre présents.  De l’émission d’il y a deux semaines, un seul rescapé donc, Pierre-Yves Geoffard.  - Pierre-Yves Geoffard est professeur à l’École d’Économie de Paris, directeur de recherche au CNRS et directeur d’Études à l’École des Hautes Études en Sciences sociales. Il travaille sur l’économie de la santé, les systèmes de santé et la protection sociale  - Carine Milcent enseigne à l’École d’Économie de Paris et est membre du CNRS. Elle est vice présidente du conseil scientifique de l' l’Agence Technique d’Information sur l’hospitalisation, l’ATIH  - Fabienne Orsi est économiste et chercheuse à l’IRD, l’Institut de recherche pour le développement. Elle y travaille sur la question de l’accès aux médicaments dans les pays du Nord comme du Sud. Elle a co-dirigé le dictionnaire des biens communs, dont la deuxième édition augmentée est parue en janvier dernier (2021) aux Presses Universitaires de France. «L'accès aux vaccins, il faut aller au-delà de la libération des brevets» (Alternatives Économiques) - Matthieu Dhenne est avocat, spécialiste des questions de propriété intellectuelle.  Il dirige l’Institut Stanislas de Boufflers qui est un think tank consacré à l’innovation.   Reportages:   ► En Afrique du Sud, deux entreprises pharmaceutiques sont mises à contribution pour produire des vaccins. Il y a Biovac, une entreprise semi-étatique située au Cap, et qui travaille à l’élaboration d'un vaccin anti-Covid avec l'entreprise californienne ImmunityBio. Il y aussi Aspen, une multinationale sud-africaine dont le siège est situé à Port-Elizabeth. Aspen a noué un partenariat avec J&J pour produire ses vaccins.  Les deux entreprises avaient déjà travaillé ensemble pour la production d'antirétroviraux. Et aujourd'hui Aspen est donc l'une des 9 entreprises dans le monde choisies pour produire le vaccin Johnson and Johnson. C'est la seule de l'hémisphère sud.  Notre correspondant à Johannesburg, Romain Chanson, s'est entretenu avec l'un des dirigeants d'Aspen. ► Soberana, c'est le nom du seul vaccin du sous-continent américain, le vaccin cubain. L'espoir de tout un pays aussi, qui traverse une de ses pires crises économiques depuis les années 90. L'île communiste a développé son propre vaccin, plusieurs vaccins même sont actuellement en cours d'essais cliniques ! Une prouesse scientifique pour ce pays de 11 millions d'habitants et un investissement qui pourrait rapporter gros au pays en termes de santé, bien sûr, mais aussi d'image et de retombées économiques. C'est un reportage Éco d'ici Éco d'ailleurs signé Domitille Piron, à La Havane.   ► Israël achève sa première campagne de vaccination contre le COVID-19. Une campagne très efficace lancée en décembre 2020. Sur place, les experts affirment que le pays aurait atteint une forme d’immunité collective. Tous les commerces ont rouvert, le port du masque n’est plus obligatoire en plein air et l’économie redémarre. L’année dernière, avant presque tout le monde, le pays avait réussi à se procurer 14 millions de doses de vaccin, achetées auprès de Pfizer BioNTech et de Moderna. Israël vient de signer une nouvelle fois avec ces laboratoires pour 16 millions de doses supplémentaires. Mais tout cela a bien sûr un coût. C'est un reportage Éco d'ici Éco d'ailleurs, de l'envoyé spécial permanent de RFI à Jérusalem, Sami Boukhelifa.

San Diego News Fix
ImmunityBio tests COVID-19 vaccine | Jonathan Wosen

San Diego News Fix

Play Episode Listen Later Oct 16, 2020 36:24


ImmunityBio, an El Segundo-based biotech firm headed by Dr. Patrick Soon-Shiong, said Thursday it had received approval from the Food and Drug Administration to begin preliminary testing of the company's COVID-19 vaccine candidate.https://www.sandiegouniontribune.com/news/california/story/2020-10-15/soon-shiong-phase-1-trial-coronavirus-vaccine